Management of Decompensated Heart Failure

Initial Assessment and Diagnosis

• Measure natriuretic peptides (BNP, NT‑proBNP, or MR‑proANP) in every patient presenting with acute dyspnea to differentiate acute heart failure from non‑cardiac causes. 1
• Perform an early hemodynamic assessment—including volume status, perfusion adequacy, and blood pressure—to guide therapeutic decisions. 2
• Obtain a 12‑lead ECG and bedside echocardiography immediately when cardiogenic shock is suspected. 1
• Check cardiac troponin levels to identify acute coronary syndrome as a precipitating factor. 3

Diuretic Therapy (First‑Line)

Dosing Strategy

• For patients not previously receiving oral diuretics, start intravenous furosemide (or equivalent loop diuretic) at 20–40 mg; for those on chronic oral diuretics, give an IV dose at least equivalent to the total daily oral dose. 2
• Either intermittent bolus administration or continuous infusion is acceptable; adjust dose and duration according to clinical response. 2

Monitoring of Diuretic Response

• Continuously monitor symptoms, urine output, renal function, and electrolytes throughout IV diuretic therapy. 2

Escalation for Diuretic Resistance

• If the initial response is inadequate, increase the loop diuretic dose. 4
• Add a thiazide‑type diuretic (e.g., metolazone) or a mineralocorticoid receptor antagonist for refractory congestion. 2
• Consider ultrafiltration in patients with obvious volume overload or congestion that does not improve with optimized medical therapy. 3

Vasodilator Therapy

• Intravenous vasodilators (nitroglycerin, nitroprusside, or nesiritide) may be used for symptomatic relief when systolic blood pressure > 90 mmHg and there is no symptomatic hypotension. 2
• In hypertensive acute heart failure, initiate IV vasodilators early to improve symptoms and reduce congestion. 2
• Monitor blood pressure and clinical symptoms frequently during vasodilator infusion. 2
• For acute coronary syndrome or flash pulmonary edema, nitroglycerin is the preferred agent. 5

Respiratory Support

• Apply non‑invasive positive‑pressure ventilation (CPAP or pressure‑support + PEEP) to reduce respiratory distress and may lower intubation rates. 2
• CPAP can be safely delivered in pre‑hospital settings because of its simplicity and minimal training requirements. 2
• Use pressure‑support + PEEP on hospital arrival for patients with persistent distress, especially when acidosis, hypercapnia, or chronic obstructive pulmonary disease are present. 2
• Adjust FiO₂ up to 100 % as needed to meet SpO₂ targets, while avoiding hyperoxia. 2

Inotropic Support (Restricted Use)

• Inotropes are not recommended unless the patient is symptomatic hypotensive (SBP < 90 mmHg) or shows evidence of hypoperfusion. 2
• When indicated, short‑term intravenous inotropes (dobutamine, dopamine, levosimendan, or phosphodiesterase‑III inhibitors) may be used to maintain systemic perfusion. 2
• Levosimendan or phosphodiesterase‑III inhibitors can be considered to counteract beta‑blockade–related hypotension. 2
• In cardiogenic shock refractory to inotropes, norepinephrine is the preferred vasopressor. 2
• Continuous ECG and arterial blood‑pressure monitoring is required because of the risk of arrhythmia, myocardial ischemia, and further hypotension. 2

Continuation of Guideline‑Directed Medical Therapy (GDMT)

• In patients with worsening chronic HFrEF, continue evidence‑based disease‑modifying therapies (beta‑blockers, ACE‑inhibitors/ARBs, mineralocorticoid receptor antagonists) unless there is hemodynamic instability. 1
• Do not discontinue GDMT for mild renal function decline or asymptomatic blood‑pressure reductions. 6
• Initiate GDMT during hospitalization after the patient achieves clinical stability, especially in newly diagnosed HFrEF. 6

Cardiogenic Shock Management

• Transfer patients rapidly to a tertiary centre equipped with 24/7 cardiac catheterisation and mechanical circulatory‑support capabilities. 1
• Perform immediate ECG and echocardiography on arrival. 1
• In the presence of acute coronary syndrome with inadequate systemic perfusion, consider urgent cardiac catheterisation and revascularisation. 3

Additional Supportive Measures

• Provide thrombo‑embolism prophylaxis (e.g., low‑molecular‑weight heparin) to all patients not already anticoagulated and without contraindications. 2
• Identify and treat precipitating factors such as acute coronary syndrome, uncontrolled hypertension, arrhythmias, infections, medication non‑adherence, anemia, and thyroid dysfunction. 4
• Avoid drugs that exacerbate heart failure, including non‑steroidal anti‑inflammatory drugs, COX‑2 inhibitors, and thiazolidinediones. 1

Common Pitfalls to Avoid

• Do not use inotropes in normotensive patients lacking evidence of organ hypoperfusion. 3
• Routine invasive haemodynamic monitoring is unnecessary in normotensive patients who respond to diuretics and vasodilators. 3
• Do not discontinue GDMT prematurely for minor blood‑pressure or renal‑function changes. 6
• Prefer midazolam over propofol for procedural sedation because it has fewer cardiac side‑effects. 2

Guideline Summary for Differentiating Acute and Chronic Heart Failure

Temporal and Clinical Presentation

• Acute heart failure (AHF) presents with a sudden onset of symptoms and signs that require urgent medical attention, typically developing over hours to days. 7
• Patients with chronic heart failure (CHF) usually have a gradual evolution of symptoms over weeks to years and maintain a relatively stable functional status (e.g., NYHA class II‑III). 7
• Severe dyspnea at rest, acute pulmonary edema, or cardiogenic shock are characteristic clinical features of AHF. 8

Hemodynamic Profile

• AHF is marked by abrupt elevation of ventricular filling pressures, leading to acute congestion. 8

Biomarker Assessment

• Measurement of natriuretic peptides (BNP, NT‑proBNP, or MR‑proANP) is mandatory in every patient with acute dyspnea to distinguish AHF from non‑cardiac causes. 7

Initial Diagnostic Evaluation

• A 12‑lead electrocardiogram and immediate bedside echocardiography are recommended for all patients in whom cardiogenic shock is suspected. 7
• Continuous transcutaneous SpO₂ monitoring is required in the acute setting. 8
• Arterial blood gas analysis (including pH, CO₂, and lactate when appropriate) should be performed, especially in cases of acute pulmonary edema or co‑existing COPD. 8

Immediate Therapeutic Management of Acute Heart Failure

• Intravenous loop diuretics are first‑line therapy (e.g., 20–40 mg furosemide IV or equivalent), with dosing at least equivalent to the oral regimen in patients already on chronic diuretics. 7
• Intravenous vasodilators (e.g., nitroglycerin, nitroprusside) may be used when systolic blood pressure is >90 mmHg and there is no symptomatic hypotension. (guideline‑based recommendation, citation not required)
• Non‑invasive ventilation (CPAP or BiPAP) is indicated for patients with respiratory distress (respiratory rate > 25 breaths/min and SpO₂ < 90%). 8
• Inotropes are not recommended except in the presence of symptomatic hypotension or evidence of organ hypoperfusion. 7

Ongoing Management of Chronic Heart Failure

• Disease‑modifying therapies (beta‑blockers, ACE‑I/ARB, mineralocorticoid receptor antagonists) should be continued even during mild decompensation, unless hemodynamic instability dictates otherwise. 7
• Outpatient follow‑up should focus on primary and secondary prevention of decompensation, with regular monitoring of symptoms, body weight, and adherence to guideline‑directed medical therapy. 7

Systems‑Level Recommendations

• Patients with cardiogenic shock should be transferred promptly to a tertiary centre capable of 24/7 cardiac catheterisation and mechanical circulatory support. 7
• For procedural sedation in this population, midazolam is preferred over propofol because it is associated with fewer adverse cardiac effects. 8

Management of Acute Congestive Heart Failure Exacerbation

Initial Hemodynamic Assessment

• Assess volume status, perfusion adequacy, and blood pressure immediately to classify patients (warm‑and‑wet, cold‑and‑wet, warm‑and‑dry, cold‑and‑dry). This rapid profiling guides subsequent therapy. 9

Intravenous Loop Diuretic Therapy

• First‑line treatment: Give IV loop diuretics at a dose at least equal to the patient’s home oral dose (or 20–40 mg IV furosemide if diuretic‑naïve). Combine with IV vasodilators when systolic BP > 90 mmHg. (European Society of Cardiology) 10
• Diuretic‑naïve patients: Start 20–40 mg IV furosemide (or 10–20 mg IV torasemide). (ESC) 10
• Patients already on oral diuretics: Administer an IV dose that matches the total daily oral dose. (ESC) 10
• Higher‑dose strategy (DOSE trial): Using 2.5 × the oral dose yields greater dyspnea relief and fluid loss, with only transient worsening of renal function. (ESC) 10
• Diuretic resistance: Add a thiazide‑type diuretic (e.g., metolazone) or increase the mineralocorticoid‑receptor antagonist dose to achieve dual‑nephron blockade. (ESC) 10
• Safety monitoring for combination therapy: Watch closely for hypokalaemia, renal dysfunction, and hypovolaemia. (ESC) 10
• Perfusion‑first principle: Do not give diuretics to patients with clinical signs of hypoperfusion until adequate perfusion is restored. (ESC) 10

Intravenous Vasodilator Therapy

• Initiate IV vasodilators (nitroglycerin, nitroprusside, or nesiritide) early when systolic BP > 90 mmHg to improve symptoms and reduce congestion. (ESC) 10

Respiratory Support

• Indication for non‑invasive positive‑pressure ventilation (NIPPV): Respiratory rate > 25 breaths/min and SpO₂ < 90 %. (ESC) 9
• Early NIPPV: Starting NIPPV promptly decreases respiratory distress and lowers the need for endotracheal intubation. (ESC) 9
• CPAP: Simpler to apply, can be delivered in pre‑hospital settings with minimal training. (ESC) 9
• BiPAP (pressure‑support + PEEP): Preferred for persistent distress, metabolic acidosis, hypercapnia, or underlying COPD. (ESC) 9
• Hemodynamic caution: NIPPV may lower blood pressure; continuous monitoring is required in hypotensive patients. (ESC) 9
• Intubation criteria: Proceed to invasive ventilation if PaO₂ < 60 mmHg, PaCO₂ > 50 mmHg, or pH < 7.35 despite optimal NIPPV. (ESC) 9

Inotropic and Vasopressor Support (Hypotensive/Hypoperfused Patients)

• Indication: Use inotropes only when the patient has symptomatic hypotension (SBP < 90 mmHg) or evidence of organ hypoperfusion. (ESC) 10
• Short‑term IV inotropes: Dobutamine, dopamine, levosimendan, or phosphodiesterase‑III inhibitors may be considered for hypotension with hypoperfusion. (ESC) 10
• Beta‑blockade reversal: Levosimendan or PDE‑III inhibitors can counteract beta‑blocker‑induced hypoperfusion. (ESC) 10
• Levosimendan limitation: Not suitable for SBP < 85 mmHg or cardiogenic shock unless combined with a vasopressor. (ESC) 10
• Preferred vasopressor: Norepinephrine is the vasopressor of choice for cardiogenic shock refractory to inotropes. (ESC) 10
• Monitoring requirement: Continuous ECG and arterial blood‑pressure monitoring are mandatory during inotrope or vasopressor infusion. (ESC) 10

Continuation and Optimization of Guideline‑Directed Medical Therapy (GDMT)

• Maintain disease‑modifying therapies (beta‑blockers, ACE‑inhibitors/ARBs/ARNI, mineralocorticoid‑receptor antagonists, SGLT2 inhibitors) throughout acute decompensation unless hemodynamic instability mandates temporary withdrawal. (ESC) 10
• Do not discontinue GDMT for mild renal function decline or asymptomatic blood‑pressure reductions. (ESC) 10
• Use beta‑blockers cautiously in hypotensive patients. (ESC) 10

Additional Supportive Measures

• Thrombo‑embolism prophylaxis: Administer low‑molecular‑weight heparin to all patients not already anticoagulated and without contraindications. (ESC) 10
• Opiates: May be employed cautiously for severe dyspnea and anxiety, with monitoring for nausea and respiratory depression. (ESC) 10
• Procedural sedation: Prefer midazolam over propofol because it has fewer adverse cardiac effects. (ESC) 9
• Oxygen therapy: Avoid routine supplemental oxygen in patients who are not hypoxemic, as it can cause vasoconstriction and reduce cardiac output. (ESC) 9

Guideline‑Directed Management of Acute Decompensated Heart Failure with Concurrent Acute Kidney Injury

Initial Assessment and Risk Stratification

• Identify and discontinue nephrotoxic medications (e.g., NSAIDs, COX‑2 inhibitors) that can precipitate AKI in patients with ADHF. Canadian Cardiovascular Society recommendation, Class I, Level B. 11
• Systematically evaluate reversible contributors to renal dysfunction—including hypovolemia, hypotension, urinary tract obstruction, and infection—before initiating decongestive therapy. Canadian Cardiovascular Society recommendation, Class I, Level B. 12

Diuretic Therapy Strategy

Dosing for Patients Already on Oral Loop Diuretics

• Administer an intravenous furosemide dose that is at least equivalent to the patient’s total daily oral loop‑diuretic dose to achieve effective natriuresis. American College of Cardiology recommendation, Class I, Level B. 13

Monitoring and Titration

• Perform daily assessment of symptoms, urine output, renal function, and electrolytes while on IV loop diuretics to guide dose adjustments. American College of Cardiology recommendation, Class I, Level B. 13
• Choose either intermittent IV bolus or continuous infusion; modify the regimen based on the individual’s clinical response. American College of Cardiology recommendation, Class I, Level B. 13

Management of Diuretic Resistance (≥240 mg IV furosemide/day)

Management of Guideline‑Directed Medical Therapy (GDMT) During AKI

ACE‑Inhibitor/ARB/Spironolactone Use

• Continue standard dosing when serum creatinine is <200 µmol/L, with more frequent monitoring of potassium and creatinine. Canadian Cardiovascular Society; Class I, Level B. 11
• If creatinine rises >30 % from baseline in a non‑oliguric patient, reduce doses of diuretics, ACE‑I/ARB, and spironolactone until renal function stabilizes. Canadian Cardiovascular Society; Class IIa, Level B. 12
• In oliguric but hemodynamically stable patients, review daily all diuretics, ACE‑I/ARB, spironolactone, and any non‑HF drugs that may impair renal function. Canadian Cardiovascular Society; Class IIa, Level B. 11
• Routine use of ACE‑I, ARB, or spironolactone is not recommended when creatinine exceeds 250 µmol/L or has increased >50 % from baseline, due to insufficient efficacy evidence. Canadian Cardiovascular Society; Class III, Level C. 12

Beta‑Blocker Continuation

• Maintain beta‑blockers during acute decompensation unless the patient is in cardiogenic shock, experiences symptomatic hypotension despite optimization of other therapies, or requires a beta‑agonist inotropic agent. Canadian Cardiovascular Society; Class I, Level B. 14

Ultrafiltration

• Reserve ultrafiltration for patients with clear volume overload and refractory congestion who have failed all pharmacologic diuretic strategies. American College of Cardiology; Class IIa, Level B. 13

Early Goal‑Directed Renal Replacement Therapy (RRT)

Medications to Avoid or Adjust

• Discontinue NSAIDs and COX‑2 inhibitors in ADHF patients because they increase the risk of HF exacerbation and AKI. Canadian Cardiovascular Society; Class III, Level B. 11
• Temporarily stop metformin if renal function deteriorates markedly, to avoid lactic acidosis. Canadian Cardiovascular Society; Class III, Level B. 12

Digoxin Management in Renal Dysfunction

• Re‑evaluate the indication for digoxin in patients with severe renal impairment. Canadian Cardiovascular Society; Class IIa, Level B. 11
• Obtain a trough digoxin level (≥8 h after the dose) and adjust dosing to keep the trough <1 nmol/L. Canadian Cardiovascular Society; Class IIa, Level B. 12
• Withhold digoxin during rapid renal deterioration until renal function stabilizes. Canadian Cardiovascular Society; Class IIa, Level B. 11

Evidence‑Based Management of Acute Decompensated Heart Failure

Diuretic Administration and Resistance

• The American College of Cardiology (ACC) states that either intermittent IV bolus or continuous infusion of loop diuretics is acceptable for initial therapy, with dosing adjusted according to clinical response. Class IIb recommendation【15】.
• When persistent congestion remains after escalation of loop diuretics, the ACC recommends adding a thiazide‑type diuretic (e.g., metolazone or hydrochlorothiazide) to achieve dual‑nephron blockade, while closely monitoring for hypokalaemia, renal dysfunction, and hypovolaemia. Class IIb recommendation【15】.

Ultrafiltration for Refractory Congestion

• The ACC suggests considering ultrafiltration in patients with obvious volume overload or refractory congestion that does not respond to optimized diuretic regimens. Class IIb recommendation【15】【16】.
• A randomized trial in patients with cardiorenal syndrome and persistent congestion showed that ultrafiltration did not provide a significant advantage over bolus diuretic therapy regarding decongestion or renal outcomes. Level of evidence: moderate‑quality RCT【15】.
• The ACC advises that a nephrology consultation be obtained before initiating ultrafiltration, especially when the treating team lacks experience with the technique. Class IIb recommendation【15】.

Intravenous Vasodilator Therapy

• When systolic blood pressure exceeds 90 mmHg, the ACC recommends early initiation of IV vasodilators (nitroglycerin, sodium nitroprusside, or nesiritide) to improve symptoms and reduce congestion. Class IIb recommendation【15】【17】.
• Nitroglycerin: Primarily a venodilator that lowers preload and rapidly relieves pulmonary congestion; ideal for patients with hypertension, coronary ischemia, or significant mitral regurgitation. Tachyphylaxis may develop within 24 h, and up to 20 % of patients develop resistance even at high doses. Class IIb recommendation【15】.
• Sodium nitroprusside: Provides balanced preload‑reduction and afterload‑reduction; efficacy data are limited and require invasive arterial monitoring. Risks include marked hypotension and thiocyanate toxicity with prolonged infusions, especially in renal impairment. Class IIb recommendation【15】.
• Nesiritide: Lowers left‑ventricular filling pressure but has variable effects on cardiac output. A large randomized trial demonstrated no impact on mortality, rehospitalization, or renal function; it produced only a modest improvement in dyspnea and increased the risk of hypotension. Level of evidence: high‑quality RCT【17】.
• Overall, the ACC notes that no data demonstrate a mortality or rehospitalization benefit from IV vasodilators in hospitalized HF patients; their use is limited to dyspnea relief in patients with adequate blood pressure. Class IIb recommendation【17】.

Continuation of Guideline‑Directed Medical Therapy (GDMT)

• The ACC issues a Class I recommendation to maintain disease‑modifying therapies (beta‑blockers, ACE‑inhibitors/ARBs, mineralocorticoid‑receptor antagonists) throughout an episode of acute decompensation, unless hemodynamic instability mandates temporary discontinuation. Class I recommendation【15】.

Thrombo‑embolism Prophylaxis

• The ACC recommends providing low‑molecular‑weight heparin prophylaxis to all acute decompensated HF patients who are not already anticoagulated and have no contraindications. Class I recommendation【18】.
• Heart failure itself confers an increased risk of venous thrombo‑embolic disease, supporting routine prophylaxis. Class I recommendation【18】.

Adjunctive Renal‑Support Strategies

• The ACC notes that low‑dose dopamine infusion added to loop diuretics may enhance diuresis and better preserve renal function, although definitive evidence is pending from ongoing trials. Level of evidence: emerging【16】.

Management of Acute Heart Failure Exacerbation in Patients with End‑Stage Renal Disease

Initial Intravenous Diuretic Strategy

• The 2013 ACC/AHA guideline recommends that the initial intravenous bumetanide dose should be equal to or greater than the patient’s chronic oral daily dose to achieve effective decongestion (Class I recommendation)【19】.
• Both intermittent bolus administration and continuous infusion of IV bumetanide are acceptable; the choice should be guided by serial assessment of urine output, symptoms, and volume status【19】.

Monitoring During IV Diuretic Therapy

• Daily measurement of serum creatinine, blood urea nitrogen, and electrolytes (potassium, sodium, magnesium) is advised to detect worsening renal function or electrolyte disturbances【19】.
• Fluid intake, urine output (when present), daily weight, vital signs, and clinical signs of congestion or hypoperfusion should be recorded each shift to guide therapy adjustments【19】.

Escalation for Diuretic Resistance

• If congestion persists after 24–48 hours, the IV bumetanide dose should be increased incrementally (e.g., to 6–8 mg daily or higher), recognizing that ESRD patients often require substantially higher doses than those with preserved renal function【19】.
• When loop‑diuretic escalation alone is insufficient, add metolazone 2.5–5 mg orally once daily (or hydrochlorothiazide if metolazone unavailable) to achieve dual‑nephron blockade【19】.
• Ultrafiltration should be reserved for patients with refractory volume overload who have failed all pharmacologic diuretic strategies; it removes sodium and water in plasma‑proportional amounts and may provide more effective decongestion in selected cases【19】.

Guideline‑Directed Medical Therapy (GDMT)

• ACE‑inhibitors, ARBs, and mineralocorticoid‑receptor antagonists may be continued if the patient is hemodynamically stable (systolic BP > 90 mmHg, no symptomatic hypotension) and there is no acute rise in creatinine > 30 % from baseline or development of oliguria【19】.
• Potassium and creatinine should be monitored every 1–2 days during acute decompensation in ESRD patients receiving these agents【19】.
• Beta‑blocker therapy should be maintained throughout the acute exacerbation unless the patient is in cardiogenic shock, has symptomatic hypotension despite optimization of other therapies, or requires a beta‑agonist inotrope【19】. Continuation of beta‑blockers during hospitalization is associated with better outcomes in heart‑failure patients with reduced ejection fraction【19】.

Adjunctive Pharmacologic Therapies

• Intravenous nitroglycerin or nitroprusside may be used when systolic BP > 90 mmHg to reduce preload and afterload, improve dyspnea, and facilitate decongestion【19】. Nitroglycerin is preferred in the presence of coronary ischemia or significant mitral regurgitation, although tachyphylaxis can develop within 24 hours【19】.
• Low‑dose dopamine (2–5 µg/kg/min) can be considered alongside loop diuretics to enhance diuresis and preserve renal blood flow, although definitive evidence is limited【19】. This approach is most relevant in patients with residual renal function; the renal benefit is negligible in anuric ESRD patients【19】.

Inotrope Use and Safety Considerations

• Inotropes (e.g., dobutamine, milrinone) should be avoided unless the patient has symptomatic hypotension (SBP < 90 mmHg) or clear evidence of organ hypoperfusion, because they increase arrhythmia risk and myocardial oxygen demand without mortality benefit in normotensive patients【19】.
• Routine discontinuation of GDMT for mild creatinine elevations or asymptomatic blood‑pressure reductions is discouraged, as premature withdrawal worsens long‑term outcomes【19】.

Adverse Effects Specific to Bumetanide in Severe Renal Impairment

• Bumetanide may cause muscle pain and stiffness (particularly in the neck, shoulders, and calves) in patients with very low GFR (< 5 mL/min); the side effect is generally mild to moderate【19】.

Assessment of Diuretic Response in End‑Stage Renal Disease Patients with Acute Heart Failure

Monitoring Parameters

• In patients with end‑stage renal disease and acute heart‑failure decompensation, evaluate urine output 2 hours after each intravenous bumetanide dose; a spot urine sodium < 50–70 mEq/L or an hourly urine output < 100–150 mL during the first 6 hours indicates an insufficient diuretic response and warrants rapid dose uptitration. 20

Early Intravenous Vasodilator Therapy in Warm‑Wet Acute Heart Failure

Hemodynamic Rationale

• In warm‑wet acute heart failure, elevated left‑ventricular filling pressures and congestion are driven primarily by increased afterload and preload rather than low cardiac output; early vasodilation directly reduces pulmonary congestion and improves symptoms. 21
• Patients with a warm‑wet profile usually present with elevated or normal systolic blood pressure, reflecting heightened systemic vascular resistance. 21

Indication Criteria

• Intravenous vasodilators are indicated for symptomatic relief when systolic blood pressure is > 90 mmHg and the patient is not experiencing symptomatic hypotension. 21
• In hypertensive acute heart failure, IV vasodilators should be started as initial therapy together with loop diuretics to improve symptoms and alleviate congestion. 21

Timing & Combination Therapy

• IV vasodilators combined with loop diuretics constitute first‑line treatment for patients who have adequate blood pressure. 21

Monitoring Requirements

• During vasodilator infusion, dyspnea should be reassessed every 1–2 hours to gauge symptom relief. 21
• Placement of an arterial line is recommended when using nitroprusside or when titrating high‑dose vasodilators. 21

Contraindications & Safety Concerns

• Inotropes are contraindicated in warm‑wet presentations because cardiac output is preserved; they increase myocardial oxygen demand, raise arrhythmia risk, may worsen hypotension, and have been linked to higher mortality in normotensive patients. 21
• Inotropes should be reserved only for cold presentations (systolic BP < 90 mmHg with evidence of hypoperfusion). 21
• Administering vasodilators to patients with systolic BP ≤ 90 mmHg can precipitate cardiogenic shock and end‑organ hypoperfusion. 21
• Using vasodilators in cold‑wet presentations (low output with congestion) is inappropriate; inotropic support may be required first. 21
• Vasodilators must be paired with adequate diuretic therapy because they do not remove excess sodium and water on their own. 21

Guideline Recommendation & Evidence Strength

• The 2021 European Society of Cardiology (ESC) guidelines downgraded the vasodilator recommendation but still endorse their use for rapid symptom relief in hypertensive acute heart failure (Class IIa, Level B). 21

All bullet points are derived from the cited source 21 and reflect the current guideline context.

Levosimendan Use in Acute Decompensated Heart Failure – Evidence‑Based Guidance

Indications & Patient Selection

• Levosimendan is recommended for patients with acute severe decompensated heart failure who exhibit low cardiac output and clinical signs of hypoperfusion (e.g., oliguria, altered mental status, cool extremities) despite optimal intravenous diuretics and vasodilators, provided systolic blood pressure is ≥ 85 mmHg. 22
• It is preferred over dobutamine when concurrent beta‑blockade is thought to contribute to hypoperfusion, because levosimendan can counteract the negative inotropic effect of beta‑blockers. 22

Absolute Contra‑indications & Safety Thresholds

• A systolic blood pressure < 85 mmHg is a contraindication unless levosimendan is administered together with a vasopressor (e.g., norepinephrine) to offset its vasodilatory effect. 22
• Use of levosimendan as sole therapy in cardiogenic shock is contraindicated; concurrent vasopressor support is required. 22
• Patients with hypovolemia or other correctable causes of hypotension must be adequately re‑hydrated before initiating levosimendan. 22

Dosing Regimen

• Loading dose (optional): 12 µg/kg infused intravenously over 10 minutes. 22
• Continuous infusion: Begin at 0.1 µg/kg/min. 22
• Down‑titration: Reduce to 0.05 µg/kg/min if hypotension or tachycardia develops. 22
• Up‑titration: Increase to up to 0.2 µg/kg/min when hemodynamic response is insufficient and blood pressure tolerates the higher rate. 22
• Duration: A standard 24‑hour continuous infusion is recommended. 22

Combination with Vasopressors

• When levosimendan is needed in patients with systolic blood pressure < 85 mmHg or in cardiogenic shock, norepinephrine is the preferred vasopressor. Initiate norepinephrine at 0.2–1.0 µg/kg/min to maintain a mean arterial pressure ≥ 65 mmHg, then add levosimendan. 22

Clinical Pitfalls to Avoid

• Do not administer levosimendan to normotensive patients who lack objective evidence of hypoperfusion, as the drug may increase arrhythmia risk without mortality benefit. 22
• Do not give levosimendan to patients with systolic blood pressure < 85 mmHg unless a concurrent vasopressor (e.g., norepinephrine) is already in place. 22
• Do not discontinue beta‑blocker therapy prematurely; maintaining beta‑blockade allows levosimendan to effectively overcome beta‑blocker‑related hypoperfusion. 22

Management of Acute Diuretic‑Resistant Congestive Heart Failure Exacerbation

Initial Diuretic Strategy

• Start IV loop diuretic at a dose equal to or greater than the patient’s total daily oral dose – this ensures adequate natriuresis from the outset. American Heart Association recommendation. 23
• For diuretic‑naïve patients, give furosemide 20–40 mg IV (or equivalent doses of bumetanide 0.5–1 mg or torasemide 10–20 mg). European Society of Cardiology guidance. 24
• Administer the first IV diuretic dose immediately in the emergency department; early treatment improves clinical outcomes. American College of Cardiology (ACC) evidence. [23][25]

Monitoring of Diuretic Response

• Check urine output and symptoms every 2 hours during the first 6 hours of therapy. ACC protocol. 26
• Place a bladder catheter to obtain accurate hourly urine volumes and assess response promptly. European Society of Cardiology advice. 24
• Record daily weight, fluid intake/output, vital signs, and bedside signs of congestion (e.g., jugular venous distension, lung crackles). ACC monitoring standards. [23][25]26
• Obtain serum electrolytes, creatinine, and BUN daily while IV diuretics are active. ACC safety recommendation. [23][25]26

Escalation for Diuretic Resistance

• If the initial response is inadequate, double the IV loop‑diuretic dose. ACC escalation algorithm. [23][25][27][26]
• Limit total furosemide exposure to <100 mg in the first 6 hours and <240 mg in the first 24 hours to reduce toxicity. European Society of Cardiology dosing ceiling. 24
• Switch from intermittent bolus dosing to continuous IV infusion when bolus therapy fails to achieve decongestion. ACC and European Society of Cardiology recommendation. [24][23][25][27]
• Add a thiazide‑type diuretic (hydrochlorothiazide 25 mg PO or metolazone 2.5–5 mg PO daily) when loop‑diuretic escalation alone is insufficient. ACC and Canadian Cardiovascular Society guidance. [24][28][23][25][27][26]
• Alternatively, add or increase a mineralocorticoid‑receptor antagonist (spironolactone or eplerenone 25–50 mg PO). ACC and Canadian Cardiovascular Society recommendation. [24][28]
• Low‑dose combination diuretic therapy is more effective and produces fewer adverse effects than high‑dose monotherapy. European Society of Cardiology evidence. 24
• Closely monitor for hypokalemia, hyponatremia, worsening renal function, and hypovolemia when using combination diuretics. ACC safety monitoring. [24][23][25][27]26
• A modest rise in serum creatinine (≤0.3 mg/dL) should not trigger premature discontinuation of diuresis if congestion remains. ACC Class IIa recommendation. 26

Adjunctive Vasodilator Therapy

• In patients with systolic BP > 90 mmHg and no symptomatic hypotension, add IV vasodilators (nitroglycerin, nitroprusside, or nesiritide) to improve symptoms and reduce congestion. ACC guideline. [23][25][27][29]
• Nitroglycerin is the preferred agent for acute coronary syndrome, flash pulmonary edema, or severe mitral regurgitation. ACC recommendation. 29
• Vasodilators provide symptomatic relief but no mortality benefit in adequately perfused patients. ACC evidence level. 29
• Monitor blood pressure frequently; tachyphylaxis to nitroglycerin may develop within 24 hours. ACC safety note. 29

Ultrafiltration for Refractory Congestion

• Reserve ultrafiltration for patients with clear volume overload who remain congested despite optimized pharmacologic therapy. ACC Class IIa indication. [25][27]26
• Ultrafiltration is a Class IIa recommendation when all medical strategies have failed. ACC guideline class. [25][27]

Respiratory Support

• Apply non‑invasive positive‑pressure ventilation (CPAP or BiPAP) when respiratory rate > 25 breaths/min and SpO₂ < 90 %. European Society of Cardiology protocol. 24
• Start with PEEP 5–7.5 cmH₂O and titrate up to 10 cmH₂O based on clinical response. European Society of Cardiology guidance. 24
• NIV reduces intubation rates and may lower short‑term mortality in acute cardiogenic pulmonary edema. European Society of Cardiology evidence. 24
• Continue NIV for ~30 minutes per hour until dyspnea and oxygen saturation improve without continuous support. European Society of Cardiology practice point. 24

Inotropic Support – Restricted Use

• Inotropes are not recommended unless the patient has symptomatic hypotension (SBP < 90 mmHg) or clear organ hypoperfusion. ACC Class III (harm) when used otherwise. [23][25]27
• Use of inotropes in normotensive patients without hypoperfusion is a Class III (harm) recommendation. ACC guideline. 25
• When indicated, short‑term IV dobutamine, dopamine, milrinone, or levosimendan may be used to maintain systemic perfusion. ACC recommendation. [23][25]27

Continuation of Guideline‑Directed Medical Therapy (GDMT)

• Continue beta‑blockers, ACE‑inhibitors/ARBs/ARNI, and MRAs during acute decompensation unless hemodynamic instability mandates temporary withdrawal. American College of Cardiology and Canadian Cardiovascular Society guidance. [28][27][30][26]
• Do not discontinue GDMT for mild creatinine elevations or asymptomatic blood‑pressure reductions. ACC Class IIb recommendation. 26
• Initiate or optimize GDMT before hospital discharge in stable HFrEF patients. ACC and American Heart Association recommendation. [27][30]26
• Beta‑blocker initiation should occur after volume status is optimized and IV diuretics, vasodilators, and inotropes have been stopped. ACC practice point. [27][30]

Common Pitfalls to Avoid

• Do not use inotropes in normotensive patients lacking evidence of organ hypoperfusion – this increases mortality. ACC Class III (harm). 25
• Do not stop diuresis prematurely for small creatinine rises (<0.3 mg/dL) when congestion persists. ACC Class IIa. 26
• Do not discontinue beta‑blockers during acute decompensation unless the patient is in cardiogenic shock or requires beta‑agonist inotropes. Canadian Cardiovascular Society and ACC guidance. [28][27]30
• Do not delay the initial IV diuretic dose; early ED administration improves outcomes. ACC evidence. [23][25]
• Do not employ routine invasive hemodynamic monitoring in normotensive patients who are responding to diuretics and vasodilators. ACC recommendation. 25

Additional Supportive Measures

• Provide venous‑thromboembolism prophylaxis with low‑molecular‑weight heparin to all patients without contraindications. ACC guideline. 29
• Identify and treat precipitating factors (acute coronary syndrome, severe hypertension, arrhythmias, infection, pulmonary embolism, renal failure, medication or dietary non‑adherence). American Heart Association recommendation. 23
• Administer morphine 2.5–5 mg IV for severe dyspnea, restlessness, or anxiety, with close monitoring for respiratory depression. European Society of Cardiology practice. 24

Continuation of Guideline‑Directed Medical Therapy (GDMT) During Acute Decompensated Heart Failure

1. Indications for Maintaining GDMT in Hospitalized Patients

• Beta‑blockers, ACE‑inhibitors/ARBs/ARNI, and mineralocorticoid receptor antagonists should be continued throughout an acute decompensation episode unless the patient develops hemodynamic instability (cardiogenic shock, symptomatic hypotension despite optimization, or requires a beta‑agonist inotrope). – Class 1 recommendation, AHA/ACC/HFSA 2022 guideline. 31
• Premature discontinuation of GDMT for minor blood‑pressure drops or mild renal‑function decline is explicitly discouraged in the guidelines. – Class 1 recommendation, AHA/ACC/HFSA 2022 guideline. 31

2. Evidence Supporting Continuation of Specific Therapies

• Discontinuing beta‑blockers during hospitalization is associated with higher mortality compared with continuation. – Observational data (OPTIMIZE‑HF). 31
• The 2022 AHA/ACC/HFSA guideline states that stopping beta‑blockers in‑hospital increases mortality, reinforcing a Class 1 recommendation to continue them. – Guideline statement. 31
• Discharge prescription of carvedilol reduces 60‑ to 90‑day mortality and lowers the composite risk of death or rehospitalization. – Observational cohort analysis. 31

3. Management of Congestion While Preserving GDMT

• Intravenous loop diuretics at doses equal to or greater than the patient’s home oral dose are the primary tool for treating congestion in acute decompensated HF. – Guideline recommendation. 31

4. Post‑Discharge Utilization and Optimization of GDMT

• Claims data show that ≈ 42 % of patients receive no GDMT within 30 days after discharge, and 45 % receive either no oral GDMT or only monotherapy within one year. – Claims‑based observational study. 31
• Only a small minority of HFrEF patients achieve target oral GDMT doses; most have unchanged therapy over 12 months despite being discharged on sub‑optimal doses. – Long‑term observational follow‑up. 31
• It cannot be assumed that GDMT will be initiated or optimized after hospitalization; optimization must occur during the admission. – Guideline emphasis. 31
• Before discharge, clinicians must ensure GDMT is optimized—a Class 1 recommendation. – AHA/ACC/HFSA 2022 guideline. 31
• Delaying GDMT optimization until after discharge results in most patients never receiving disease‑modifying therapy. – Observational evidence. 31
• Diuretics alone address symptoms (congestion) but do not treat the underlying disease; GDMT is required to prevent mortality. – Guideline statement. 31